Recap: Reata Pharmaceuticals Q4 Earnings


Shares of Reata Pharmaceuticals RETA were unchanged after the company reported Q4 results.

Quarterly Results

Earnings per share increased 21.38% over the past year to ($1.25), which beat the estimate of ($2.16).

Revenue of $3,192,000 rose by 19.46% year over year, which beat the estimate of $1,440,000.

Looking Ahead

Reata Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Mar 01, 2021

Time: 08:30 AM

ET Webcast URL:


52-week high: $209.91

52-week low: $88.17

Price action over last quarter: down 33.78%

Company Profile

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

Market News and Data brought to you by Benzinga APIs
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!